by The pharmaceutical contract manufacturing market size is poised to grow by USD 330.52 billion by 2033 from USD 172 billion in 2023, exhibiting a CAGR of 6.80% during the forecast period 2024 to 2033.
Key Points
- North America contributed 36% of market share in 2023.
- Asia-Pacific is estimated to expand the fastest CAGR between 2024 and 2033.
- By service, the pharmaceutical manufacturing services segment has held the largest market share of 33% in 2023.
- By service, the drug development services segment is anticipated to grow at a remarkable CAGR of 8.9% between 2024 and 2033.
- By end-user, the big pharmaceutical companies segment generated over 42% of revenue share in 2023.
- By end-user, the small & mid-sized pharmaceutical companies segment is expected to expand at the fastest CAGR over the projected period.
The pharmaceutical contract manufacturing market refers to the outsourcing of pharmaceutical production to third-party manufacturers. This practice allows pharmaceutical companies to focus on research, development, and marketing while leveraging the expertise and capabilities of contract manufacturing organizations (CMOs) to produce drugs on their behalf. The market encompasses a wide range of services, including formulation development, manufacturing, packaging, and quality control.
Get a Sample Report: https://www.precedenceresearch.com/sample/3750
Growth Factors:
Several factors are driving the growth of the pharmaceutical contract manufacturing market. Firstly, increasing cost pressures and the need for operational efficiency are compelling pharmaceutical companies to outsource manufacturing activities to specialized CMOs. Additionally, the complexity of drug development and stringent regulatory requirements are encouraging companies to seek the expertise of CMOs with advanced manufacturing capabilities and regulatory compliance. Moreover, the globalization of pharmaceutical supply chains and the emergence of new markets are expanding the opportunities for contract manufacturing services, driving market growth further.
Pharmaceutical Contract Manufacturing Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 6.80% |
| Global Market Size in 2023 | USD 172 Billion |
| Global Market Size by 2033 | USD 330.52 Billion |
| U.S. Market Size in 2023 | USD 43.34 Billion |
| U.S. Market Size by 2033 | USD 84.07 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Service and By End User |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: U.S. Insulation Market Size to Worth USD 19.96 Bn by 2033
Opportunities
The pharmaceutical contract manufacturing market presents numerous opportunities for both pharmaceutical companies and CMOs. For pharmaceutical companies, outsourcing manufacturing allows them to reduce capital expenditures, minimize risks associated with capacity constraints, and accelerate time-to-market for new drugs. They can also leverage the specialized expertise and infrastructure of CMOs to access advanced technologies and manufacturing processes. On the other hand, CMOs can capitalize on the growing demand for outsourcing services by investing in state-of-the-art facilities, expanding their service offerings, and forging strategic partnerships with pharmaceutical companies to enhance their market presence and competitiveness.
Challenges
Despite its growth prospects, the pharmaceutical contract manufacturing market faces several challenges. One significant challenge is maintaining quality and compliance standards across geographically dispersed manufacturing sites, especially in the context of diverse regulatory requirements in different regions. Ensuring seamless communication and coordination between pharmaceutical companies and CMOs also poses a challenge, particularly in complex supply chains involving multiple stakeholders. Moreover, the threat of intellectual property infringement and the need to protect confidential information present ongoing challenges for both parties involved in contract manufacturing arrangements. Additionally, fluctuations in demand, evolving market dynamics, and geopolitical uncertainties can impact the stability and predictability of contract manufacturing operations, requiring agile strategies to mitigate risks and capitalize on emerging opportunities.
Pharmaceutical Contract Manufacturing Market Companies
- Lonza Group
- Catalent, Inc.
- Patheon (Now part of Thermo Fisher Scientific)
- Recipharm AB
- Boehringer Ingelheim
- Dr. Reddy’s Laboratories
- Jubilant Life Sciences
- Fareva
- Vetter Pharma
- Evonik Industries
- WuXi AppTec
- Pfizer CentreOne
- Almac Group
- AbbVie Contract Manufacturing
- Samsung Biologics
Data Sources and Methodology
To gather comprehensive insights on the Global Pharmaceutical contract manufacturing Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.
We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Pharmaceutical contract manufacturing Market.
The most resonating, simple, genuine, and important causes because of which you must decide to buy the Pharmaceutical contract manufacturing market report exclusively from precedence research
- The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2023 to 2032.
Key Features of the Report:
- Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
- Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
- Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.
Market Segmentation:
By Service
- Pharmaceutical Manufacturing Services
- Pharmaceutical API Manufacturing Services
- Pharmaceutical FDF Manufacturing Services
- Drug Development Services
- Biologic Manufacturing Services
- Biologic API Manufacturing Services
- Biologic FDF Manufacturing Services
By End User
- Big Pharmaceutical Companies
- Small & Mid-Sized Pharmaceutical Companies
- Generic Pharmaceutical Companies
- Other End Users (Academic Institutes, Small CDMOs, and CROs)
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Reasons to Consider Purchasing the Report:
- Enhance your market research capabilities by accessing this comprehensive and precise report on the global Pharmaceutical contract manufacturing market.
- Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
- Benefit from in-depth research and analysis of the latest trends shaping the global Pharmaceutical contract manufacturing market.
- Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Pharmaceutical contract manufacturing market.
- Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
- Discover not only the cutting-edge technological advancements in the global Pharmaceutical contract manufacturing market but also the strategic plans of industry leaders.
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pharmaceutical Contract Manufacturing Market
5.1. COVID-19 Landscape: Pharmaceutical Contract Manufacturing Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pharmaceutical Contract Manufacturing Market, By Service
8.1. Pharmaceutical Contract Manufacturing Market, by Service, 2024-2033
8.1.1. Pharmaceutical Manufacturing Services
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Pharmaceutical API Manufacturing Services
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Pharmaceutical FDF Manufacturing Services
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Drug Development Services
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Biologic Manufacturing Services
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Biologic API Manufacturing Services
8.1.6.1. Market Revenue and Forecast (2021-2033)
8.1.7. Biologic FDF Manufacturing Services
8.1.7.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Pharmaceutical Contract Manufacturing Market, By End User
9.1. Pharmaceutical Contract Manufacturing Market, by End User, 2024-2033
9.1.1. Big Pharmaceutical Companies
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Small & Mid-Sized Pharmaceutical Companies
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Generic Pharmaceutical Companies
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Other End Users (Academic Institutes, Small CDMOs, and CROs)
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Pharmaceutical Contract Manufacturing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Service (2021-2033)
10.1.2. Market Revenue and Forecast, by End User (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.1.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.1.4.2. Market Revenue and Forecast, by End User (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.2. Market Revenue and Forecast, by End User (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.4.2. Market Revenue and Forecast, by End User (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.5.2. Market Revenue and Forecast, by End User (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.6.2. Market Revenue and Forecast, by End User (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.4.2. Market Revenue and Forecast, by End User (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.5.2. Market Revenue and Forecast, by End User (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.6.2. Market Revenue and Forecast, by End User (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.2. Market Revenue and Forecast, by End User (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.4.2. Market Revenue and Forecast, by End User (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.5.2. Market Revenue and Forecast, by End User (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.6.2. Market Revenue and Forecast, by End User (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.5.2. Market Revenue and Forecast, by End User (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.5.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.5.4.2. Market Revenue and Forecast, by End User (2021-2033)
Chapter 11. Company Profiles
11.1. Lonza Group
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Catalent, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Patheon (Now part of Thermo Fisher Scientific)
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Recipharm AB
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Boehringer Ingelheim
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Dr. Reddy’s Laboratories
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Jubilant Life Sciences
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Fareva
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Vetter Pharma
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Evonik Industries
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Unlocking Market Insights through Data Excellence
The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.
Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com
Precedence Statistics – Empowering Your Data Insights
Contact Us
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
